Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03949764 · ClinicalTrials.gov registry record · Phase 4
The Kentucky Viral Hepatitis Treatment Study
A Phase 4 study of Hepatitis C and Opioid-Related Disorders, sponsored by Jennifer Havens.
- Completed
- Registry status
- Phase 4
- Development phase
- 374
- Enrollment target
- 1
- Study location
NCT03949764: Completed Phase 4 study of Hepatitis C and Opioid-Related Disorders, sponsored by Jennifer Havens.
NCT03949764 is a Phase 4 study of Hepatitis C and Opioid-Related Disorders that has completed, run by Jennifer Havens. The registered enrollment target is 374 participants, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03949764, a Phase 4 study of Hepatitis C and Opioid-Related Disorders, has completed, sponsored by Jennifer Havens.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 374 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.
Primary Outcome
Defined as receiving the first dose of medication, to be measured by number of pills left and viral load.
Conditions Studied
Interventions
- DRUG Sofosbuvir/velpatasvir (Epclusa®)
Study Locations (1)
Kentucky
- ARH Medical Mall - Hazard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 4 |
What the finished NCT03949764 record still lists
NCT03949764 is an interventional study that assigns participants to a tested intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Sofosbuvir/velpatasvir (Epclusa®) is the first listed.
NCT03949764 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03949764 about?
NCT03949764 is a clinical study titled "The Kentucky Viral Hepatitis Treatment Study". The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to ...
What is the current status of trial NCT03949764?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 374 participants. The study started on 2019-09-23. Estimated completion is 2025-06-30.
What conditions does trial NCT03949764 study?
This clinical trial studies the following conditions: Hepatitis C, Opioid-Related Disorders, Injection Drug Use.
What interventions are being tested in trial NCT03949764?
The interventions under investigation include: Sofosbuvir/velpatasvir (Epclusa®) (DRUG).
Who is sponsoring clinical trial NCT03949764?
This trial is sponsored by Jennifer Havens, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03949764 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03949764's enrollment target sits among peer trials
374 30th of 106 higher than 77 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI